Get the Stockscreener App
2.84
7.19%
-0.22
Grace Therapeutics Inc stock is traded at $2.84, with a volume of 62,160.
It is down -7.19% in the last 24 hours and down -27.18% over the past month.
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.
See More
Previous Close:
$3.06
Open:
$3.05
24h Volume:
62,160
Relative Volume:
0.69
Market Cap:
$38.10M
Revenue:
-
Net Income/Loss:
$-11.61M
P/E Ratio:
-2.1937
EPS:
-1.2946
Net Cash Flow:
$-11.82M
1W Performance:
-16.96%
1M Performance:
-27.18%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$2.8202
$3.08
1-Week Range:
$2.8202
$3.4594
52-Week Range:
$2.8202
$4.965
Grace Therapeutics Inc Stock (GRCE) Company Profile
Name
Grace Therapeutics Inc
Sector
Industry
Phone
609-322-1602
Address
103 CARNEGIE CENTER, PRINCETON
Compare GRCE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRCE
Grace Therapeutics Inc
|
2.84 | 38.10M | 0 | -11.61M | -11.82M | -1.2946 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Grace Therapeutics Inc Stock (GRCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-20 | Upgrade | B. Riley FBR | Neutral → Buy |
| Jan-13-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-29-19 | Initiated | B. Riley FBR | Buy |
| Jul-18-19 | Initiated | Oppenheimer | Outperform |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
View All
Grace Therapeutics Inc Stock (GRCE) Latest News
Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference - The Manila Times
Can Grace Therapeutics' Novel aSAH Treatment Impress Investors at Major Healthcare Conference? - StockTitan
Grace Therapeutics reports positive Phase 3 trial results for GTx-104 - MSN
Grace Therapeutics secures up to $30 million financing - MSN
GRCE: STRIVE-ON Results Reported - MSN
Corcept Therapeutics stock soars to all-time high of $62.34 - MSN
Grace Therapeutics’ (GRCE) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
H.C. Wainwright reiterates buy on Grace Therapeutics stock By Investing.com - Investing.com Australia
H.C. Wainwright reiterates buy on Grace Therapeutics stock - Investing.com India
Promising Potential of Grace Therapeutics’ GTX-104 Drives Buy Rating - TipRanks
Grace Therapeutics On Track For NDA Submission Of GTx-104 For Aneurysmal Subarachnoid Hemorrhage - Nasdaq
GRACE THERAPEUTICS Earnings Results: $GRCE Reports Quarterly Earnings - Nasdaq
Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update - The Manila Times
Grace Therapeutics Reports Positive Phase 3 STRIVE-ON Trial Results for GTx-104 and Secures $30 Million in Financing; NDA Submission Expected by Mid-2025 - Nasdaq
Grace Therapeutics Inc. (GRCE) reports earnings - Quartz
Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results - TradingView
Grace Reports Clinical Trial Victory and Major Cash Infusion in Latest Earnings - StockTitan
Grace Therapeutics, Inc. SEC 10-Q Report - TradingView
Grace Therapeutics secures up to $30 million financing By Investing.com - Investing.com Nigeria
Grace Therapeutics secures $15m for GTx-104 pre-commercial development - MSN
Grace therapeutics announces private placement financing of $30 million - MSN
Sector Update: Health Care Stocks Softer Late Afternoon -February 10, 2025 at 04:01 pm EST - Marketscreener.com
Sector Update: Health Care Stocks Softer Late Afternoon - TradingView
Grace Therapeutics Shares Rise After Private Placement Financing of up to $30 Million - Marketscreener.com
Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study - Benzinga
Grace Therapeutics Announces Financing of $30 Million - citybiz
Grace Therapeutics meets main goal in late stage trial for its aneurysmal SAH treatment - Seeking Alpha
Grace Therapeutics Phase 3 STRIVE-ON Safety Study Meets Primary Goal - Nasdaq
Grace Therapeutics reports positive Phase 3 trial results for GTx-104 By Investing.com - Investing.com South Africa
Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH - The Manila Times
We're (SUPER) Sorry for your Team's Loss: Vivid Seats and The Bouqs Co. Launch Consolation Contest - The Manila Times
Nasdaq, Inc. Announces Cash Tender Offers for Up to $200 Million Outstanding Debt Securities - The Manila Times
Grace Therapeutics Secures Up to $30 Million in Financing Led by Nantahala Capital and ADAR1 Partners for GTx-104 Development - Nasdaq
Grace Therapeutics Lands Strategic $30M Financing Deal: Major Boost for Critical Brain Hemorrhage Treatment - StockTitan
Grace's GTx-104 Clinical Data Reveals Major Breakthrough for Brain Hemorrhage Treatment - StockTitan
Converge Reports Preliminary Fourth Quarter and Fiscal Year 2024 Financial Results and Conference Call Details - Yahoo Canada Finance
Grace Therapeutics (GRCE) to Release Quarterly Earnings on Monday - Defense World
GraceKennedy buys full ownership of Catherine’s Peak Bottling Company - Yahoo
MaRS appoints Grace Lee Reynolds as CEO and welcomes new leaders to the board - Yahoo Finance
Corcept Therapeutics stock soars to all-time high of $70.78 - MSN
University President Mourns Student Who Died in Midair Collision - Yahoo Finance
The Orlando Credit Union Charitable Foundation Opens Applications for 2025 Grace Chewning Scholarship Fund - Yahoo Finance
Snowflake CEO: DeepSeek is the real deal, and other OpenAI rivals are coming - Yahoo Finance
Viracta Therapeutics strikes deal to avoid default - MSN
3 US Penny Stocks With Market Cap Under $70M - Simply Wall St
Nav Welcomes Grace Liu as Chief Financial Officer - Yahoo Finance
HEAVY.AI Announces Availability of Analytics Platform Accelerated by NVIDIA Grace Hopper Superchip - Yahoo Finance
Grace Therapeutics Inc Stock (GRCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):